Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.70 |
| ▸ | CSNK2A2 | P19784 | 13/20 | 0.70 |
| ▸ | CSNK2B | P67870 | 13/20 | 0.70 |
| ▸ | PIM3 | Q86V86 | 13/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 13/20 | 0.70 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854483 | 0.89 | PIM1 (0.87) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1854138 | 0.82 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL13650259 | 0.74 | PIM1 (0.75) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1850611 | 0.73 | PIM1 (0.73) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1851344 | 0.72 | PIM1 (0.71) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL13650251 | 0.71 | PIM1 (0.71) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1853289 | 0.71 | PIM1 (0.71) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1852531 | 0.71 | PIM1 (0.72) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1851543 | 0.71 | PIM1 (0.80) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL1852630 | 0.71 | PIM1 (0.68) | PIM1CSNK2A2CSNK2BPIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |